Alaunos reports ALN1003 shows broad metabolic improvements in obese mouse studies

Alaunos Therapeutics reported preclinical data showing its ALN1003 candidate demonstrated consistent improvements across multiple metabolic markers including body weight, insulin sensitivity, and liver health in diet-induced obese mice. The positive early-stage results support continued development of the non-hormonal, non-incretin obesity treatment candidate.